LOG IN
SIGN UP
MARKET
MTEM
MTEM
Molecular Templates Inc
NASDAQ
Real-time Quotes | Nasdaq Last Sale
0.9714
-0.0386
-3.82%
After Hours: 0.9900 +0.0186 +1.91% 18:11 05/26 EDT
OPEN
1.000
PREV CLOSE
1.010
HIGH
1.010
LOW
0.9400
VOLUME
151.58K
TURNOVER
0
52 WEEK HIGH
9.30
52 WEEK LOW
0.9400
MARKET CAP
54.73M
P/E (TTM)
-0.7015
1D
5D
1M
3M
1Y
5Y
Molecular Templates to Present at Upcoming Investor Conferences
AUSTIN, Texas, May 17, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, e...
GlobeNewswire · 05/17 20:05
Stifel Adjusts Molecular Templates' Price Target to $9 From $11, Reiterates Buy Rating
MT Newswires · 05/16 08:54
Molecular Templates Q1 EPS $(0.38) Up From $(0.51) YoY, Sales $8.50M Up From $3.22M YoY
Molecular Templates (NASDAQ:MTEM) reported quarterly losses of $(0.38) per share. This is a 25.49 percent increase over losses of $(0.51) per share from the same period last year. The company reported $8.50 million in
Benzinga · 05/12 21:08
Molecular Templates GAAP EPS of -$0.38 beats by $0.04, revenue of $8.49M beats by $3.35M
Molecular Templates press release (NASDAQ:MTEM): Q1 GAAP EPS of -$0.38 beats by $0.04. Revenue of $8.49M (+163.7% Y/Y) beats by $3.35M. “We continue to make meaningful progress in advancing our
Seekingalpha · 05/12 20:39
-- Earnings Flash (MTEM) MOLECULAR TEMPLATES Reports Q1 Revenue $8.5M
MT Newswires · 05/12 16:44
Catalyst Pharmaceutical (CPRX) Misses Q1 Earnings and Revenue Estimates
Catalyst (CPRX) delivered earnings and revenue surprises of -14.29% and 0.19%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/10 21:25
Rock star Growth Puts Molecular Templates (NASDAQ:MTEM) In A Position To Use Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Simply Wall St. · 05/06 14:18
Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates
Nektar (NKTR) delivered earnings and revenue surprises of 31.94% and 3.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/05 21:55
No Data
Learn about the latest financial forecast of MTEM. Analyze the recent business situations of Molecular Templates Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 7 analysts
Strong Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
57.14%Strong Buy
42.86%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average MTEM stock price target is 10.58 with a high estimate of 18.00 and a low estimate of 4.500.
Current 0.9714
EPS
Actual
Estimate
-0.43-0.32-0.22-0.11
Institutional Holdings
Institutions: 117
Institutional Holdings: 40.52M
% Owned: 71.93%
Shares Outstanding: 56.34M
TypeInstitutionsShares
Increased
19
1.64M
New
10
1.58M
Decreased
29
957.52K
Sold Out
13
1.94M
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.99%
Pharmaceuticals & Medical Research
+0.43%
Key Executives
Non-Executive Chairman/Independent Director
Harold Selick
President/Chief Operating Officer
Jason Kim
Chief Executive Officer/Chief Scientific Officer/Director
Eric Poma
Chief Financial Officer/Senior Vice President - Finance/Chief Accounting Officer/Controller/Treasurer
Sean McLennan
General Counsel
Megan Filoon
Other
Roger Waltzman
Independent Director
Gabriela Gruia
Independent Director
David Hirsch
Independent Director
David Hoffmann
Independent Director
Kevin Lalande
Independent Director
Jonathan Lanfear
Independent Director
Scott Morenstein
Independent Director
Corazon Sanders
No Data
No Data
About MTEM
Molecular Templates, Inc. is a clinical stage biopharmaceutical company that is focused on the discovery and development of differentiated, targeted, biologic therapeutics for cancer and other serious diseases. The Company utilizes its biologic drug platform to design and generate engineered toxin bodies (ETBs). ETBs use a genetically engineered version of the Shiga-like Toxin A subunit (SLTA), a ribosome inactivating bacterial protein. The Company is developing ETBs for various targets, including CD20, CD38, HER2, and PD-L1. CD20 is central to B cell malignancies and is clinically validated as a target for the treatment of lymphomas and autoimmune disease. CD38 has been validated as a clinical target in the treatment of multiple myeloma. HER2 is clinically validated as a target for the treatment of solid tumors including breast and gastric cancer. PD-L1 is central to immune checkpoint pathways and is a target expressed in a variety of solid tumor cancers.
Webull offers kinds of Molecular Templates Inc stock information, including NASDAQ:MTEM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MTEM stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading MTEM stock methods without spending real money on the virtual paper trading platform.